FANCD2 Antibody - BSA Free

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - Effects of FANCD2 knockdown on levels of cell cycle regulators. Caki-1 cells were transfected with control siRNA (siCon) or FANCD2 siRNA (siFD2#2) and treated with AICAR for 24 h. The levels of FANCD2, p15Ink4B, and p21Cip1 were evaluated by immunoblotting. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/2211-5463.12185) licensed under a CC-BY license.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - Resistance of FANCA-mutant cells with defective FANCD2 function to hydrogen peroxide (H2O2). Representative images illustrating staining for subnuclear FANCD2 foci in isogenic fibroblast pairs, either deficient for FANCD2 (PD20) or FANCA (PD220) and their respective wild-type (wt) complemented counterparts. Foci were visualized three hours after treatment with H2O2 (25 uM for 2 hours). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2008/821529/) licensed under a CC-BY license.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - AMPK-activating AICAR treatment activates FANCD2, a pivotal molecule of Fanconi anemia DNA damage signaling pathway. AICAR treatment induces FANCD2 monoubiquitination in transformed normal fibroblasts (GM00637I). GM00637I cells were treated with 1 mm 2-deoxyglucose, 0.25 mM AICAR, or 1 mm phenformin for 24 h. Lysates were subjected to western blotting with FANCD2 Antibody, phospho-AMPKalpha1 (T172), and AMPKalpha and beta-actin. In FANCD2 blots, the position of monoubiquitinated FANCD2 (Ub-FANCD2) is indicated by an arrow. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/2211-5463.12185) licensed under a CC-BY license.

Simple Western: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - Simple Western lane view shows a specific band for FANCD2 in 0.1 mg/ml of HeLa lysate using FANCD2 Antibody. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Immunocytochemistry/Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - Analysis using the Biotin conjugate of FANCD2 Antibody. FANCD2 colocalizes in vivo with another protein in SiHa cells after cell exposure to IR. Proliferating SiHa cells were exposed to 10 Gy of IR and double color immunofluorescence staining was performed after 8 h. Images were captured in a Kodak digital image system on a Leica fluorescence microscope.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - AICAR-induced FANCD2 monoubiquitination is dependent on AMPK. Inhibitor of AMPK blocks AICAR-induced FANCD2 monoubiquitination in GM00637I normal fibroblasts. Cells were pretreated with 5 um of Compound C (an AMPK inhibitor) 1 h before treatment with 0.25 mm AICAR for 24 h. Cell lysates were subjected to immunoblotting with FANCD2 Antibody to visualize monoubiquitinated FANCD2 (Ub-ANCD2). Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/2211-5463.12185) licensed under a CC-BY license.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - The FA-BRCA Pathway Is Activated on the Sex Chromosomes during Meiosis. Schematic of the FA-BRCA pathway. FA proteins analyzed in this study are shown in color. Western blot analysis with three independent anti-FANCD2 antibodies (G33, E33, and Novus NB100-182 antibody: NB). K561R, PD20 cells expressing a mutated form of FANCD2 incapable of monoubiquitination; WT, PD20 cells complemented with wild-type FANCD2; Vector, PD20 cells containing empty vector. Image collected and cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S2211124716313298), licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - HES1K109E mutation does not impair MMC-induced HES1 foci formation. HeLa cells transfected with HA-tagged HES1 or HES1K109E coding vectors were processed for immunofluorescence 16 h following treatment with MMC (120 ng/ml). Cells were double-stained with anti-HA and anti-FANCD2 antibodies (mouse anti-HA at 1:500; rabbit anti-FANCD2, Novus Biologicals NB100-182 at 1:2000) followed with secondary antibodies (Goat anti-mouse Alexafluor-555, ThermoScientific A-32727 and goat anti-rabbit Alexafluor-488, ThermoScientific, A-11008). Cell nuclei were labelled with TO-PRO-3 Iodide stain (1:400, ThermoScientific, T3605). Cells were visualized at 100x magnification. Image collected and cropped by CiteAb from the following publication (//bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3243-7), licensed under a CC-BY license.

Immunohistochemistry: FANCD2 Antibody - BSA Free [NB100-182] - FANCD2 Antibody [NB100-182] - The tissue sections were incubated with a primary antibody cocktail of FANCD2 Antibody (NB100-182) at a dilution of 1:1000 & a monoclonal anti-Ki67 mouse antibody at a dilution of 1:150 for 1 h at room temperature. Then the slides were incubated with a secondary antibody cocktail containing FITC conjugated anti-rabbit IgG and Alexafluor 594 donkey anti-mouse secondary. The sections were mounted on glass slides using a DAPI-containing embedding medium (Vysis Dapi 1, Abbott Laboratories, Downers Grove, IL, USA), then analyzed under a fluorescence microscope. FANCD2 (top) foci positive NSCL tumor, and FANCD2 (bottom)foci negative NSCL tumor. Magnification: 1000x. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fonc.2014.00368/abstract), licensed under a CC-BY license.

Western Blot: FANCD2 Antibody [NB100-182] - Analysis of FANCD2 (Molecular weight: 164.1 KDa) using the HRP conjugate of FANCD2 Antibody (lot C) in HeLa WCE.

Western Blot: FANCD2 Antibody [NB100-182] - Functional assessment of Fanconi anemia pathway. Western blot with FANCD2 Antibody of non-FA control lymphoblasts (LCL), proband LCL-A-2017, proband LCL-B-2017, FANCB mutant (null) LCL, and FANCD2 mutant (null) LCL. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/mgg3.350), licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: FANCD2 Antibody [NB100-182] - Mouse Embryonic Fibroblasts Untreated and treated with Mitomycin C for 24hr with FANCD2 Antibody diluted 1:500 in 15%BCS+0.3% Triton X 100 in PBS. This image was submitted via customer Review.

Immunohistochemistry: FANCD2 Antibody [NB100-182] - Staining of human prostate, glandular epithelium using FANCD2 Antibody. Image using the Biotin format of this antibody.

Representative images of the cellular response to RS (induced by a low dose of hydroxyurea; HU) in U2OS cells, as determined by IF staining for gamma H2AX and FANCD2A selected cell is defined by the yellow arrow, and is enlarged in the bottom panel. Scale bars are indicated.

FANCD2 was detected in immersion fixed A431 human skin carcinoma cell line using Rabbit anti-FANCD2 Antigen Affinity Purified Polyclonal Antibody conjugated to DyLight 550 (Catalog # NB100-182R) (red) at 5 µg/mL overnight at 4C. Cells were counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Western blot analysis of FANCD2 & ERCC1 expression in lung cancer cell H1299 following treatment with veliparib. PAR protein level was reduced at 6 h post veliparib 5 μM exposure & maintained at low levels through 48 h in the H1299 cells. However, FANCD2 & ERCC1 protein expression raised simultaneously in these cells post treatment with veliparib. The data suggest that veliparib induces compensatory activation of alternative DNA-repair pathways. C is control (without treatment). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fonc.2014.00368/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - Workflow for MS-based quantification of CFS associated proteins. (A) Experimental workflow for SILAC-based quantitative MS identification of CFS associated proteins. (B) Flow cytometry analysis of cell cycle distribution of SILAC labeled cells used for enrichment of CFSs as illustrated in (A). (C) IF of FANCD2 & EdU incorporation to assess formation of FANCD2 foci at late replicating regions with & without APH treatments. Cells were synchronized as in (A) & (B). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31180492), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - The response to replication stress is a defining feature for Ewing sarcoma compared to the PHATE_1-high developmental context. (A) Western blot showing expression of Fanconi Anemia proteins FANCA, FANCD2, & FANCI in TC32 (Ewing sarcoma cell line) compared to IMR90 (fibroblast cell line); (B) Bar-plot showing the impact of FANC genes knockdown on cell viability in TC32 compared to IMR90; (C) Western blot showing the expression of FEN1 in Ewing sarcoma cell lines TC32, EWS502, & CHLA10 compared to IMR90; (D) Line plot showing the viability of Ewing sarcoma cells compared to IMR90 with increasing doses of FEN1 inhibitor. (** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32290418), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Activation of FANCD2 monoubiquitination following treatment with the EZH2 inhibitor EPZ-6438(A-C) MCF10A (A), HCT116 p53+/+ & p53-/- (B), & U2OS (C) cells were treated with the indicated concentrations of the EZH2-specific inhibitor EPZ-6438 for 24 h (A & B) or 24, 48, & 72 h (C). Whole-cell lysates were prepared & immunoblotted with the indicated antibodies. L.E., light exposure; D.E., dark exposure; L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI, relative band intensity. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29100324), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Inhibition of class I & II HDACs attenuates FANCD2 & FANCI monoubiquitination in BJ-TERT cells(A) & (B), HeLa cells were pre-treated with the indicated concentrations of trichostatin A (TSA) (A) or vorinostat (SAHA) (B) for 4 h, followed by co-incubation with (+) & without (-) 200 nM MMC for a further 20 h. Whole-cell lysates were prepared & immunoblotted with anti-FANCD2, anti-FANCI, anti-CHK1 pS345, anti-CHK2 pT68, anti-H4K16ac, & anti-alpha -Tubulin antibodies. (C) & (D), BJ-TERT cells were treated identically to that described for HeLa cells above. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCD2 or FANCI. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29100324), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - Representative images of the cellular response to RS (induced by a low dose of hydroxyurea; HU) in U2OS cells, as determined by IF staining for gamma H2AX & FANCD2A selected cell is defined by the yellow arrow, & is enlarged in the bottom panel. Scale bars are indicated. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.16940), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Functional evaluation of FANCBWT & mutant cDNA. Proband fibroblasts, FANCB mutant (null) fibroblasts & BJ control fibroblasts were HPV16 E6E7 transformed. Either empty vector, wild‐type FANCBcDNA, or mutant FANCBcDNA (p.A319*) was introduced into proband fibroblasts & FANCB mutant (null) fibroblasts. After puromycin selection, cells were cultured with or without MMC 1 μM for 24 hr, after which cells were harvested for the FANCD2 & HA western blot assays Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29193904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - BRD4770-induced activation of the FA pathway may occur via inhibition of the PRC2 complex(A) U2OS cells were incubated in the absence (NT) or presence of BRD4770, DZNep, UNC0646, & DZNep & UNC0646 combined (4 μM each) for 24 h. Whole-cell lysates were prepared & immunoblotted with anti-FANCD2, anti-FANCI, anti-EZH2, & anti-alpha -Tubulin antibodies. (B) U2OS cells were incubated in the absence or presence of 2, 5, & 10 μM BRD4770 for 24, 48, or 72 h. Whole-cell lysates were prepared & immunoblotted with anti-FANCD2, anti-FANCI, anti-CHK1 pS345, anti-EZH2, anti-H3K27me3, & anti-alpha -Tubulin antibodies. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI, relative band intensity. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29100324), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - Chemical library screening for small molecules that inhibit the Fanconi anemia pathway. (A) Schematic of the screening for small molecules that inhibit IR-induced FANCD2 foci formation. (B) Representative photomicrographs of EGFP-FANCD2 foci in PD20F-EGFP-FANCD2 cells untreated & treated with the indicated compounds at the indicated concentration. The cells were treated with compounds immediately before irradiation (15 Gy), & fixed after 12 hours. (C) FANCD2 foci in HeLa cells untreated & treated with the indicated compounds at the indicated concentration. The cells were fixed 8 hours after irradiation (10 Gy) & immunostained with anti-FANCD2 antibody. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-11-26), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - AMPK‐activating AICAR treatment activates FANCD2, a pivotal molecule of Fanconi anemia DNA damage signaling pathway. (A) AICAR treatment induces FANCD2 monoubiquitination in transformed normal fibroblasts (GM00637I). GM00637I cells were treated with 1 mm 2‐deoxyglucose, 0.25 mM AICAR, or 1 mm phenformin for 24 h. Lysates were subjected to western blotting with anti‐FANCD2, phospho‐AMPK alpha 1 (T172), & AMPK alpha & beta ‐actin. In FANCD2 blots, the position of monoubiquitinated FANCD2 (Ub‐FANCD2) is indicated by an arrow. (B) AICAR treatment induces formation of FANCD2 nuclear foci in GM00637I fibroblasts. Cells grown on coverslips in 12‐well plates were treated with 0.25 mm AICAR for 24 h. Cells were immunostained with FANCD2 antibody & Alexa 488‐conjugated anti‐rabbit secondary antibody. FANCD2 foci were visualized by confocal microscopy. Representative images are shown at the top. The number of foci per cell was counted & plotted for ≥ 20 cells (bottom panel). The values represent the mean ± SEM (Student's t‐test, ***P 5 gamma H2AX foci were scored. At least 300 nuclei were scored for each treatment & this experiment was performed three times with similar results. Error bars represent the standard errors of the means from three independent experiments. (B) BJ-TERT cells were incubated with (+) & without (-) 0.4 μM etoposide (VP-16), in the absence or presence of 10 μM BRD4770, 5 μM GSK-J1 & 2.5 μM BIX01294, for 24 h. Whole-cell lysates were immunoblotted with anti-gamma H2AX & anti-PCNA (loading control) antibodies. (C) U2OS cells were incubated in the absence (NT) or presence of 200 nM MMC or 5 & 10 μM BRD4770 for 24 h. Whole-cell lysates were prepared & immunoblotted with anti-FANCD2, anti-FANCA, anti-UBE2T, anti-USP1, anti-CHK1 pS345, anti-RPA, anti-RPA pS4/8, & anti-alpha -Tubulin antibodies. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCD2; RBI, relative band intensity. (D) U2OS cells were incubated in the absence or presence of 2, 5, & 10 μM BRD4770 for 24, 48, or 72 h. Cells were fixed in ice-cold ethanol, stained with propidium iodide, & analyzed by flow cytometry. Cell cycle stage distributions were determined using FlowJo v10.2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29100324), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - AICAR‐induced FANCD2 monoubiquitination is dependent on AMPK. (A) Inhibitor of AMPK blocks AICAR‐induced FANCD2 monoubiquitination in GM00637I normal fibroblasts. Cells were pretreated with 5 μm of Compound C (an AMPK inhibitor) 1 h before treatment with 0.25 mm AICAR for 24 h. Cell lysates were subjected to immunoblotting with FANCD2 to visualize monoubiquitinated FANCD2 (Ub‐FANCD2). (B) AMPK inhibitor abrogates AICAR‐induced FANCD2 nuclear foci formation in GM00637I fibroblasts. GM006387I cells grown on coverslips were pretreated with 5 μm Compound C 1 h prior to 0.25 mm AICAR treatment for 24 h. FANCD2 foci were visualized by immunofluorescence staining & confocal microscopy. Representative images are shown at the top. The number of foci per cell was counted & plotted for ≥ 20 cells (bottom panel). The values represent the mean ± SEM (Student's t‐test, *P < 0.05; ***P < 0.001). (C) Knockdown of AMPK alpha 1 inhibits AICAR‐induced FANCD2 monoubiquitination in Caki‐1 cells. Caki‐1 cells were transfected with siRNAs (siControl or siAMPK#8) & after 48 h, AICAR was treated for 24 h. FANCD2 monoubiquitination was monitored by immunoblotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28174693), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - LNK depletion restores FA-like human progenitor cells. a depicts a schematic overview of isolation of primary human HSPCs for lentiviral transduction followed by CFC assay. b UCB-derived CD34 + cells were sequentially infected with lentiviruses expressing shRNA to Luciferase (Luc) or FANCD2 (D2) with GFP marker, followed by shRNA to Luc or LNK with mCherry marker. GFP + mCherry + cells were then sorted & plated onto semi-solid methylcellulose media. Colony forming progenitor numbers are shown with a two-tailed Student's t-test. Representative data from two independent repeats are shown. c TF-1 cells with shRNA-mediated depletion of LNK or FANCD2 or CRISPR/Cas9-mediated depletion of LNK were analyzed for depletion efficiency by western blot. Luc, luciferase. gRNA, guide RNA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30254368), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - SAN1 functions independently of the FA pathway & does not affect FA pathway activation. a, b CSAs of HeLa WT & SAN1−/− cells treated with scrambled ctrl siRNA or FANCD2 siRNA, in response to Cisplatin & MMC (N = 3). Statistical significance determined by two-way ANOVA. Error bars denote s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c Immunoblot showing siRNA knockdown of FANCD2 in HeLa WT & SAN1−/− cells. d IF staining of FANCD2 foci in HeLa WT cells & SAN1−/− cells treated with 0.045 μM MMC. e Immunoblot of FANCD2 showing mono-ubiquitylation in HeLa WT & SAN1−/− cells treated with vehicle or 0.045 μM MMC. f, g CSAs of HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA & exposed to Cisplatin or MMC. Statistical significance was determined by two-way ANOVA test. h Immunoblot of SNM1A in HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29968717), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - SAN1 functions independently of the FA pathway & does not affect FA pathway activation. a, b CSAs of HeLa WT & SAN1−/− cells treated with scrambled ctrl siRNA or FANCD2 siRNA, in response to Cisplatin & MMC (N = 3). Statistical significance determined by two-way ANOVA. Error bars denote s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c Immunoblot showing siRNA knockdown of FANCD2 in HeLa WT & SAN1−/− cells. d IF staining of FANCD2 foci in HeLa WT cells & SAN1−/− cells treated with 0.045 μM MMC. e Immunoblot of FANCD2 showing mono-ubiquitylation in HeLa WT & SAN1−/− cells treated with vehicle or 0.045 μM MMC. f, g CSAs of HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA & exposed to Cisplatin or MMC. Statistical significance was determined by two-way ANOVA test. h Immunoblot of SNM1A in HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29968717), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - The FANCD2 NLS is required for the nuclear localization of a subset of FANCI.(A) FA-D2 patient cells or FA-D2 cells stably expressing FANCD2-WT were incubated in the absence (NT) or presence of MMC for 24 h, fixed, stained with rabbit polyclonal anti-FANCD2 or anti-FANCI antibody & counterstained with phalloidin & DAPI. AF-488, Alexa Fluor 488. (B) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2-∆N57, FANCD2-∆N100, & FANCD2-3N were incubated in the absence (NT) or presence of MMC for 24 h, fixed, & stained with rabbit polyclonal anti-FANCI antibody, & counterstained with phalloidin & DAPI. At least 300 cells were scored for cytoplasmic (Cyto.), nuclear (Nucl.), & both cytoplasmic & nuclear (Both) localization of FANCI. (C) COS-7 cells were transiently transfected with no DNA, FANCI-GFP, FANCI-GFP plus FANCD2-V5-WT, or FANCI-GFP plus FANCD2-V5-∆N57. Whole-cell lysates were immunoprecipitated with anti-V5 or anti-GFP antibodies & immune complexes immunoblotted with anti-GFP & anti-V5 antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24278431), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Functional assessment of Fanconi anemia pathway. (a) The experimental scheme for MMC treatment. Twenty‐four hours after plating, cells were cultured with or without MMC 1 μM for an additional 24 hr, after which the cells were harvested for western blot or immunostaining. (b) Western blot with FANCD2 antibody of BJ, proband fibroblasts, FANCB mutant (null) fibroblasts & FANCD2 mutant (null) fibroblasts. (c) Western blot with FANCD2 antibody of non‐FA control lymphoblasts (LCL), proband LCL‐A‐2017, proband LCL‐B‐2017, FANCB mutant (null) LCL, & FANCD2 mutant (null) LCL. (d) Representative figures of FANCD2 foci formation in the indicated cells. (e) Quantification of FANCD2 foci formation following treatment with or without 1 μM MMC. Experiments were performed in triplicate. One hundred cells were counted for each experiment Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29193904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - The FAN1 PIP-box motif is not required for FAN1 foci formation upon exposure to MMC. a Total cell extracts & chromatin-enriched fractions of U2OS cells expressing the indicated eGFP-FAN1 variants, treated or mock-treated with MMC (150 ng/ml, 24 h), were analysed by immunoblotting using the indicated antibodies. A representative blot of three independent experiments is shown. b Cells as in a were immunostained with anti-FANCD2 antibody. Representative images are shown. Scale bar: 25 μm. c, d Quantification of eGFP-FAN1 foci count (c) & the sum of their intensities (d) was obtained from QIBC analysis of b. Median levels are indicated by black bars. Statistical analyses were carried out using unpaired, two-tailed t-tests. P values expressed as ***(P < 0.01) were considered significant, n = 3. e Total cell extracts derived from cells as in a, treated or mock-treated with MMC (150 ng/ml, 24 h), were incubated with anti-eGFP affinity resin. Inputs & immunoprecipitates were analysed by immunoblotting with the indicated antibodies. A representative blot of two independent experiments is shown Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29051491), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - Functional assessment of Fanconi anemia pathway. (a) The experimental scheme for MMC treatment. Twenty‐four hours after plating, cells were cultured with or without MMC 1 μM for an additional 24 hr, after which the cells were harvested for western blot or immunostaining. (b) Western blot with FANCD2 antibody of BJ, proband fibroblasts, FANCB mutant (null) fibroblasts & FANCD2 mutant (null) fibroblasts. (c) Western blot with FANCD2 antibody of non‐FA control lymphoblasts (LCL), proband LCL‐A‐2017, proband LCL‐B‐2017, FANCB mutant (null) LCL, & FANCD2 mutant (null) LCL. (d) Representative figures of FANCD2 foci formation in the indicated cells. (e) Quantification of FANCD2 foci formation following treatment with or without 1 μM MMC. Experiments were performed in triplicate. One hundred cells were counted for each experiment Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29193904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - DNA damage & cell survivalas a function of FANCD2 status. (a) Representative images of the formation of gamma H2AX foci in PD20 versus wild-typecomplemented cells 30 minutes after completion of H2O2 treatment. (b) Quantification of gamma H2AX foci response. Data represent means with upper standard error based on two independent experiments. (c) G2-type chromosomal aberrations are expressed as breaks per cell as a function of increasing H2O2 concentration in FANCD2-deficient andwild-type complemented PD20 cells. Data represent means with SEM based on at least three repeat experiments. (d) Apoptosis induction by H2O2 (50 μM) in cells with or without wild-type FANCD2 using fluorescence microscopy to assess apoptotic morphology by DAPI staining & flow cytometric analysis for sub-G1 DNA content. Representative experiments based on theapoptotic response at 24 hours are shown (similar results were obtained at 48 hours & with 25 μM H2O2). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/18483568), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - The FANCD2 NLS is required for efficient FANCD2 & FANCI monoubiquitination & chromatin association.(A) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2-K561R, FANCD2-∆N57, FANCD2-∆N100 & FANCD2-3N were incubated in the absence & presence of 250 nM MMC for 18 h, & whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI & alpha -tubulin. The FANCD2 & FANCI L/S ratios are the ratios of monoubiquitinated to nonubiquitinated protein, & were calculated by measuring protein band intensities using ImageJ image processing & analysis software (//rsb.info.nih.gov/ij/). (B & C) FA-D2 cells stably expressing FANCD2-WT, FANCD2-∆N57, FANCD2-∆N100 & FANCD2-3N were treated as above & cell pellets were fractionated into soluble (S) & chromatin-associated (C) fractions. Fractions were immunoblotted with antibodies against V5, FANCI, alpha -tubulin & H2A. W, unfractionated whole cell extract. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24278431), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - AICAR‐induced FANCD2 monoubiquitination requires FANCA. (A) AICAR‐induced FANCD2 monoubiquitination does not occur in transformed FANCA−/− fibroblasts originated from a patient with defective FANCA. Transformed FANCA−/− (GM06914B) or normal fibroblasts (GM00637I) were treated with 0.25 mm AICAR for 24 h, & monoubiquitinated FANCD2 (Ub‐FANCD2) was visualized by immunoblotting. (B) AICAR‐induced FANCD2 nuclear foci formation is abrogated in FANCA−/− fibroblasts. FANCD2 nuclear foci were visualized by immunofluorescence staining & confocal microscopy. (C) Knockdown of FANCA abolishes FANCD2 monoubiquitination after AICAR treatment in Caki‐1 cells. Caki‐1 cells were transfected with FANCA‐targeting siRNAs (siFANCA#5 or siFANCA#6), treated with AICAR & subjected to FANCD2 immunoblotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28174693), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Acetaldehyde toxicity to human FANCD2‐deleted human cells & FANCD2 ubiquitylation in BRCA2‐deleted cellsA, BHuman DLD1 cells in which FANCD2 was deleted with CRISPR/Cas9 & control cells were incubated with the indicated concentrations of cisplatin (A) or acetaldehyde (B) for 6 days before processing for dose‐dependent viability assays. Graphs are representative of two independent experiments, each performed in triplicate. Error bars represent SD of triplicate values obtained from a single experiment. Inset, Western blot detection of FANCD2 expression. SMC1 was used as a loading control.CBRCA2‐proficient (+BRCA2) or BRCA2‐deficient (−BRCA2) DLD1 cells were incubated with 4 mM acetaldehyde for 48 h before being processed for immunoblotting as indicated.DH1299 cells expressing a DOX‐inducible BRCA2 shRNA were grown in the presence or absence of DOX & transfected with control or FANCD2 siRNA before being processed for immunoblotting as indicated. DOX, doxycycline. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28729482), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Functional assessment of Fanconi anemia pathway. (a) The experimental scheme for MMC treatment. Twenty‐four hours after plating, cells were cultured with or without MMC 1 μM for an additional 24 hr, after which the cells were harvested for western blot or immunostaining. (b) Western blot with FANCD2 antibody of BJ, proband fibroblasts, FANCB mutant (null) fibroblasts & FANCD2 mutant (null) fibroblasts. (c) Western blot with FANCD2 antibody of non‐FA control lymphoblasts (LCL), proband LCL‐A‐2017, proband LCL‐B‐2017, FANCB mutant (null) LCL, & FANCD2 mutant (null) LCL. (d) Representative figures of FANCD2 foci formation in the indicated cells. (e) Quantification of FANCD2 foci formation following treatment with or without 1 μM MMC. Experiments were performed in triplicate. One hundred cells were counted for each experiment Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29193904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - SAN1 functions independently of the FA pathway & does not affect FA pathway activation. a, b CSAs of HeLa WT & SAN1−/− cells treated with scrambled ctrl siRNA or FANCD2 siRNA, in response to Cisplatin & MMC (N = 3). Statistical significance determined by two-way ANOVA. Error bars denote s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c Immunoblot showing siRNA knockdown of FANCD2 in HeLa WT & SAN1−/− cells. d IF staining of FANCD2 foci in HeLa WT cells & SAN1−/− cells treated with 0.045 μM MMC. e Immunoblot of FANCD2 showing mono-ubiquitylation in HeLa WT & SAN1−/− cells treated with vehicle or 0.045 μM MMC. f, g CSAs of HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA & exposed to Cisplatin or MMC. Statistical significance was determined by two-way ANOVA test. h Immunoblot of SNM1A in HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29968717), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - AICAR‐induced FANCD2 monoubiquitination requires FANCA. (A) AICAR‐induced FANCD2 monoubiquitination does not occur in transformed FANCA−/− fibroblasts originated from a patient with defective FANCA. Transformed FANCA−/− (GM06914B) or normal fibroblasts (GM00637I) were treated with 0.25 mm AICAR for 24 h, & monoubiquitinated FANCD2 (Ub‐FANCD2) was visualized by immunoblotting. (B) AICAR‐induced FANCD2 nuclear foci formation is abrogated in FANCA−/− fibroblasts. FANCD2 nuclear foci were visualized by immunofluorescence staining & confocal microscopy. (C) Knockdown of FANCA abolishes FANCD2 monoubiquitination after AICAR treatment in Caki‐1 cells. Caki‐1 cells were transfected with FANCA‐targeting siRNAs (siFANCA#5 or siFANCA#6), treated with AICAR & subjected to FANCD2 immunoblotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28174693), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - BRCA2-deficient cells accumulate single-stranded DNA lesions in G2. a gamma H2AX foci analysis in early mitotic cells. Cells were untreated, or treated with RO-3306 (10 µM, 24 h) to delay mitotic entry, & released for 1 h before analysis of gamma H2AX & FANCD2 foci pairs in early mitotic cells. Representative images are shown (left). Analysis is by an unpaired two-tailed t-test. n = 3. Scale bars 10 µm. b–g Cells treated with the indicated siRNAs or mirin (50 µM, 5 h) were incubated with EdU for 30 min & then analyzed for gamma H2AX & RPA foci in G2 cells (EdU–, 2N DNA content). Representative deconvolved images are shown (b). Quantification of gamma H2AX foci (top, c–g) & RPA+ gamma H2AX foci (bottom, c–g) for BRCA2-deficient cells (c), cells transfected with siRNAs (d, RAD51; e SMARCAL1; f EXO1 & DNA2), & cells treated with mirin (g) are shown. n ≥ 3. Scale bars 10 µm. h, i Cells were incubated with EdU as in b before analysis of gamma H2AX & pCHK2-T68 (h) or pATM-S1981 (i) foci in G2 cells. Representative deconvolved images with magnified inset highlighting foci co-localization are shown (left in each panel). n ≥ 3. Scale bars 10 µm. Error bars s.d. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired two-tailed t-test) Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-00634-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - SAN1 functions independently of the FA pathway & does not affect FA pathway activation. a, b CSAs of HeLa WT & SAN1−/− cells treated with scrambled ctrl siRNA or FANCD2 siRNA, in response to Cisplatin & MMC (N = 3). Statistical significance determined by two-way ANOVA. Error bars denote s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c Immunoblot showing siRNA knockdown of FANCD2 in HeLa WT & SAN1−/− cells. d IF staining of FANCD2 foci in HeLa WT cells & SAN1−/− cells treated with 0.045 μM MMC. e Immunoblot of FANCD2 showing mono-ubiquitylation in HeLa WT & SAN1−/− cells treated with vehicle or 0.045 μM MMC. f, g CSAs of HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA & exposed to Cisplatin or MMC. Statistical significance was determined by two-way ANOVA test. h Immunoblot of SNM1A in HeLa WT & SAN1−/− cells treated with ctrl or SNM1A siRNA Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29968717), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - BRCA2 deficiency causes DNA under replication that results in abnormal mitoses. a–cBRCA2∆Ex3-4/– cells released for 22 h from serum starvation to increase mitotic cells, incubated w/ EdU for 1 h, & then analyzed for mitotic DNA synthesis. Early mitotic cells defined as being in prophase, prometaphase,/metaphase analyzed for EdU foci that co-localize w/ FANCD2 foci pairs. a Representative images of mitotic DNA synthesis. Scale bars 10 µm. b Percent early mitotic cells containing EdU foci, analyzed by an unpaired two-tailed t-test. n = 3. c FANCD2 foci pairs w//w/out EdU foci co-localization. Graphs represent pooled results of 3 independent experiments, each analyzed by a two-tailed Mann–Whitney test. Median FANCD2 foci pair number, red bars. Image collected & cropped by CiteAb from following publication (//www.nature.com/articles/s41467-017-00634-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - The FANCD2 NLS is required for efficient FANCD2 & FANCI monoubiquitination & chromatin association.(A) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2-K561R, FANCD2-∆N57, FANCD2-∆N100 & FANCD2-3N were incubated in the absence & presence of 250 nM MMC for 18 h, & whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI & alpha -tubulin. The FANCD2 & FANCI L/S ratios are the ratios of monoubiquitinated to nonubiquitinated protein, & were calculated by measuring protein band intensities using ImageJ image processing & analysis software (//rsb.info.nih.gov/ij/). (B & C) FA-D2 cells stably expressing FANCD2-WT, FANCD2-∆N57, FANCD2-∆N100 & FANCD2-3N were treated as above & cell pellets were fractionated into soluble (S) & chromatin-associated (C) fractions. Fractions were immunoblotted with antibodies against V5, FANCI, alpha -tubulin & H2A. W, unfractionated whole cell extract. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24278431), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - Detection of FANCD2 foci formation in human lung tumors by the FATSI staining analysis. The paraffin-embedded lung tumor tissues sections were deparaffinized & rehydrated. The tissue sections were incubated with a primary antibody cocktail of rabbit polyclonal FANCD2 antibody (Novus Biologicals, Littleton, CO, USA) at a dilution of 1:1000 & a monoclonal anti-Ki67 mouse antibody (Dako, Carpenteria, CA, USA) at a dilution of 1:150 for 1 h at room temperature. Sections then were incubated with a secondary antibody cocktail containing FITC conjugated anti-rabbit IgG & Alexafluor 594 donkey anti-mouse secondary for 1 h at room temperature. The sections were mounted on glass slides using a 4′ 6-diamidino-2-phenylindole (DAPI)-containing embedding medium (Vysis Dapi 1, Abbott Laboratories, Downers Grove, IL, USA). The slides were analyzed under a fluorescence microscope. (A) FANCD2 foci positive NSCL tumor, & (B) FANCD2 foci negative NSCL tumor. Magnification: 1000×. Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fonc.2014.00368/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: FANCD2 Antibody - BSA Free [NB100-182] - Normal DNA damage responses in FANCD2-deficient cells treated with hydrogen peroxide (H2O2). (a) Illustration of RAD51 foci formation in PD20 & PD20-wtD2 cells 5 hours after exposure to MMC (0.25 μg/mL for 1 hour) or H2O2 (25 μM for 2 hours). (b) Induction of RAD51 foci formation above background levels by MMC or H2O2. Because equal drug concentrations were used, rather than isoeffective concentrations with regard to cell survival, the extent of foci induction between FANCD-deficient & -complemented cells is not directly comparable. Data represent means with upperstandard error based on three independent repeats. (c) DNA synthesis measured by BrdU pulse labeling in cells treated with ionizing radiation (IR, 8 Gy) or H2O2 (25 μM). Data represent means with upper standard error based on twoindependent experiments. (d) Cell cycle distribution of propidium-iodide cell populations by flow cytometry. A representative experiment is shown. Percentages of cells in the G1, S, & G2 (and M) phases of the cell cycle are indicated. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/18483568), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Dicer inhibition prevents FANCD2 foci formation after replication stress without affecting FANCD2 mono-ubiquitylation.(A) HCT116 cells were treated with control or Dicer siRNA & then with aphidicolin to induce replicative stress. They were then stained for FANCD2 & analyzed by immunofluorescence microscopy. (B) Quantification of the experiments in panel (A) showing the percentage of FANCD2 positive cells. Error bars represent the SD of three independent experiments. To score the FANCD2 positive cells a threshold value was calculated on the base of the average number of foci in control cells for each replicate, using Image J. Unpaired t-test: *p < 0.05. (C) FANCD2 foci formation in WT & Dicer Ex5/Ex5 cells after replication stress induced by aphidicolin. (D) Quantification of the experiments in panel (C) showing the percentage of FANCD2 positive cells. Error bars represent the SD of three independent experiments. Unpaired t-test: **p < 0.005. (E) Western blotting showing the levels of FANCD2 mono-ubiquitylation (L-FANCD2) after siRNA-mediated inhibition of Dicer, in the presence or absence of replication stress induced by aphidicolin. Vinculin was used as a loading control. (F) Western blotting showing FANCD2 mono-ubiquitylation levels after Drosha inhibition by siRNA. (G) FANCD2 mono-ubiquitylation levels in WT & Dicer Ex5/Ex5 cells assayed by western blotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31320994), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Acetaldehyde toxicity to human FANCD2‐deleted human cells & FANCD2 ubiquitylation in BRCA2‐deleted cellsA, BHuman DLD1 cells in which FANCD2 was deleted with CRISPR/Cas9 & control cells were incubated with the indicated concentrations of cisplatin (A) or acetaldehyde (B) for 6 days before processing for dose‐dependent viability assays. Graphs are representative of two independent experiments, each performed in triplicate. Error bars represent SD of triplicate values obtained from a single experiment. Inset, Western blot detection of FANCD2 expression. SMC1 was used as a loading control.CBRCA2‐proficient (+BRCA2) or BRCA2‐deficient (−BRCA2) DLD1 cells were incubated with 4 mM acetaldehyde for 48 h before being processed for immunoblotting as indicated.DH1299 cells expressing a DOX‐inducible BRCA2 shRNA were grown in the presence or absence of DOX & transfected with control or FANCD2 siRNA before being processed for immunoblotting as indicated. DOX, doxycycline. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28729482), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - The FAN1 PIP-box motif is not required for FAN1 foci formation upon exposure to MMC. a Total cell extracts & chromatin-enriched fractions of U2OS cells expressing the indicated eGFP-FAN1 variants, treated or mock-treated with MMC (150 ng/ml, 24 h), were analysed by immunoblotting using the indicated antibodies. A representative blot of three independent experiments is shown. b Cells as in a were immunostained with anti-FANCD2 antibody. Representative images are shown. Scale bar: 25 μm. c, d Quantification of eGFP-FAN1 foci count (c) & the sum of their intensities (d) was obtained from QIBC analysis of b. Median levels are indicated by black bars. Statistical analyses were carried out using unpaired, two-tailed t-tests. P values expressed as ***(P < 0.01) were considered significant, n = 3. e Total cell extracts derived from cells as in a, treated or mock-treated with MMC (150 ng/ml, 24 h), were incubated with anti-eGFP affinity resin. Inputs & immunoprecipitates were analysed by immunoblotting with the indicated antibodies. A representative blot of two independent experiments is shown Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29051491), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - AMPK‐activating AICAR treatment activates FANCD2, a pivotal molecule of Fanconi anemia DNA damage signaling pathway. (A) AICAR treatment induces FANCD2 monoubiquitination in transformed normal fibroblasts (GM00637I). GM00637I cells were treated with 1 mm 2‐deoxyglucose, 0.25 mM AICAR, or 1 mm phenformin for 24 h. Lysates were subjected to western blotting with anti‐FANCD2, phospho‐AMPK alpha 1 (T172), & AMPK alpha & beta ‐actin. In FANCD2 blots, the position of monoubiquitinated FANCD2 (Ub‐FANCD2) is indicated by an arrow. (B) AICAR treatment induces formation of FANCD2 nuclear foci in GM00637I fibroblasts. Cells grown on coverslips in 12‐well plates were treated with 0.25 mm AICAR for 24 h. Cells were immunostained with FANCD2 antibody & Alexa 488‐conjugated anti‐rabbit secondary antibody. FANCD2 foci were visualized by confocal microscopy. Representative images are shown at the top. The number of foci per cell was counted & plotted for ≥ 20 cells (bottom panel). The values represent the mean ± SEM (Student's t‐test, ***P < 0.001). (C) AICAR treatment induces FANCD2 monoubiquitination in Caki‐1 cells. Caki‐1 cells were treated with 0.25 mm AICAR for 24 h & monoubiquitination of FANCD2 was monitored as in (A). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28174693), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - AICAR‐induced FANCD2 monoubiquitination is dependent on AMPK. (A) Inhibitor of AMPK blocks AICAR‐induced FANCD2 monoubiquitination in GM00637I normal fibroblasts. Cells were pretreated with 5 μm of Compound C (an AMPK inhibitor) 1 h before treatment with 0.25 mm AICAR for 24 h. Cell lysates were subjected to immunoblotting with FANCD2 to visualize monoubiquitinated FANCD2 (Ub‐FANCD2). (B) AMPK inhibitor abrogates AICAR‐induced FANCD2 nuclear foci formation in GM00637I fibroblasts. GM006387I cells grown on coverslips were pretreated with 5 μm Compound C 1 h prior to 0.25 mm AICAR treatment for 24 h. FANCD2 foci were visualized by immunofluorescence staining & confocal microscopy. Representative images are shown at the top. The number of foci per cell was counted & plotted for ≥ 20 cells (bottom panel). The values represent the mean ± SEM (Student's t‐test, *P < 0.05; ***P < 0.001). (C) Knockdown of AMPK alpha 1 inhibits AICAR‐induced FANCD2 monoubiquitination in Caki‐1 cells. Caki‐1 cells were transfected with siRNAs (siControl or siAMPK#8) & after 48 h, AICAR was treated for 24 h. FANCD2 monoubiquitination was monitored by immunoblotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28174693), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: FANCD2 Antibody - BSA Free [NB100-182] - Acetaldehyde toxicity to human FANCD2‐deleted human cells & FANCD2 ubiquitylation in BRCA2‐deleted cellsA, BHuman DLD1 cells in which FANCD2 was deleted with CRISPR/Cas9 & control cells were incubated with the indicated concentrations of cisplatin (A) or acetaldehyde (B) for 6 days before processing for dose‐dependent viability assays. Graphs are representative of two independent experiments, each performed in triplicate. Error bars represent SD of triplicate values obtained from a single experiment. Inset, Western blot detection of FANCD2 expression. SMC1 was used as a loading control.CBRCA2‐proficient (+BRCA2) or BRCA2‐deficient (−BRCA2) DLD1 cells were incubated with 4 mM acetaldehyde for 48 h before being processed for immunoblotting as indicated.DH1299 cells expressing a DOX‐inducible BRCA2 shRNA were grown in the presence or absence of DOX & transfected with control or FANCD2 siRNA before being processed for immunoblotting as indicated. DOX, doxycycline. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28729482), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

An intracellular stain was performed on A431 human skin carcinoma cell line using Rabbit anti-FANCD2 Affinity Purified Polyclonal Antibody conjugated to DyLight 550 (Catalog # NB100-182R, blue histogram) or matched control antibody (Catalog # NBP2-24981R, orange histogram) at 2.5 µg/mL for 30 minutes at RT.

FANCD2 was detected in immersion fixed U-2 OS human osteosarcoma cell line using Rabbit anti-FANCD2 Antigen Affinity Purified Polyclonal Antibody conjugated to Biotin (Catalog # NB100-182B) at 5 µg/mL overnight at 4C. Cells were stained using Streptavidin conjugated to DyLight 550 (red) and counterstained with DAPI (blue). Cells were imaged using a 100X objective and digitally deconvolved.

• Reactivity: Hu, Mu, Rt, Av, Ca, Ma, Pm, Ze
• Applications: WB, Simple Western, ChIP, Flow, ICC/IF, IHC, IP, KD, WB, ChIP, KD, KO
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

FANCD2 Antibody - BSA Free Summary

• Immunogen: This FANCD2 Antibody was developed against human FANCD2 fusion protein (N-terminal fragment). [Swiss-Prot #Q9BXW9]
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: FANCD2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Chromatin Immunoprecipitation (ChIP) reported in scientific literature (PMID 28196964)
  • Chromatin Immunoprecipitation reported in scientific literature (PMID 28196964)
  • Flow Cytometry 2 - 5 ug/ml
  • Immunoblotting reported in multiple pieces of scientific literature
  • Immunocytochemistry/ Immunofluorescence 5 ug/ml
  • Immunohistochemistry 2.5-5.0 ug/ml
  • Immunohistochemistry-Paraffin 2.5-5.0 ug/ml
  • Immunoprecipitation 1:10-1:500
  • Knockdown Validated
  • Knockout Validated
  • RNA Inhibition reported in scientific literature (PMID 27694619)
  • Simple Western 1:25
  • Western Blot 1 - 2 ug/ml
• Application Notes: By Western blot, this antibody should recognize a band at ~166 kDa (post-translationally modified form). Additional bands may be seen at lower molecular weights. For immunofluorescence, it has been tested in human MMC and IR treated MEF cells. In Simple Western only 10 - 15 uL of the recommended dilution is used per data point.
  See Simple Western Antibody Database for Simple Western validation: Tested in HeLa lysate 0.1 mg/mL, separated by Size, antibody dilution of 1:25, apparent MW was 160 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue.
• Theoretical MW: 164.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  HeLa Whole Cell Lysate

Reactivity Notes

Primate reactivity reported in literature (PMID: 21421661). Canine reactivity reported in literature (PMID: 27257868). Zebrafish reactivity reported in scientific literature (PMID: 30540754). Rat reactivity reported in multiple pieces of scientific literature. Kangaroo reactivity reported in scientific literature (PMID: 24982423).

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for FANCD2 Antibody - BSA Free

• DKFZp762A223
• FA4
• FACD
• FAD
• FAD2
• FA-D2
• FADFAD2
• FANCD
• FANCD2
• Fanconi anemia complementation group D2
• Fanconi anemia group D2 protein
• Fanconi anemia, complementation group D2
• FLJ23826
• FPN1
• HFE4
• IREG1
• Protein FACD2
• SLC11A3

Background

Fanconi Anemia (FA) is an autosomal-recessive cancer-prone disorder characterized by congenital defects, progressive bone marrow failure, increased chromosomal breakage, defective DNA repair and cellular hypersensitivity to mitomycin C. Fanconi Anemia Complementation Group D (FANCD) is comprised of two separate proteins, FANCD1/BRCA2 and FANCD2. LYRIC/MTDH, an RNA binding protein, regulates expression of FANCD2 and FANCD1 (1). FANCD2 is mapped to chromosome 3p25.3, has a theoretical molecular weight of 166 kDa and is localized in the nucleus. FANCD2 is involved in the regulation of DNA-binding transcription factor activity and DNA stability through accurate and efficient pairing of homologs during meiosis to promote repair of double-strand DNA breaks (2). Ubiquitination is required for FANCD2 to bind to chromatin. In response to DNA damage, FANCD2 is monoubiquinated to result in colocalization with other proteins (BRCA1 and BRCA2) involved in homology-directed DNA repair in the nucleus and is deubiquitinated upon DNA repair completion.

References

1. Bi, J., Areecheewakul, S., Li, Y., Yang, S., Zhang, Y., Ebeid, K., . . . Meng, X. (2019). MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. Gynecol Oncol, 155(2), 349-358. doi:10.1016/j.ygyno.2019.08.014

2. Balcerek, J., Jiang, J., Li, Y., Jiang, Q., Holdreith, N., Singh, B., . . . Tong, W. (2018). Lnk/Sh2b3 deficiency restores hematopoietic stem cell function and genome integrity in Fancd2 deficient Fanconi anemia. Nat Commun, 9(1), 3915. doi:10.1038/s41467-018-06380-1

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FANCD2 Antibody (NB100-182)(227)

Publications using NB100-182

• Kusano Y, Kinugasa Y, Tashiro S et Al. Chromosomal rearrangements associated with SMC5/6 deficiency in DNA replication Genes Cells 2024-11-14 [PMID: 39540295]
• Blaize JL, Garzon JLN, Howlett NG. FANCD2 genome binding is nonrandom and is enriched at large transcriptionally active neural genes prone to copy number variation Functional & Integrative Genomics 2024-10-04 [PMID: 39365306]
• Harada N, Asada S, Jiang L et Al. The splicing factor CCAR1 regulates the Fanconi anemia/BRCA pathway Mol Cell 2024-07-11 [PMID: 39025073]
• Liu Z, Jiang H, Lee SY et Al. FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition Cell Rep 2024-07-08 [PMID: 38985669]
• Audrey A, Kok YP, Yu S, de Haan L et Al. RAD52-dependent mitotic DNA synthesis is required for genome stability in Cyclin E1-overexpressing cells Cell Rep 2024-04-16 [PMID: 38625790]
• Kenichiro Matsuzaki, Akira Shinohara, Miki Shinohara Human AAA+ ATPase FIGNL1 suppresses RAD51-mediated ultra-fine bridge formation Nucleic Acids Research 2024-06-10 [PMID: 38597669]
• Esin Isik, Kaustubh Shukla, Michaela Pospisilova, Christiane König, Martin Andrs, Satyajeet Rao, Vinicio Rosano, Jana Dobrovolna, Lumir Krejci, Pavel Janscak MutS beta -MutL beta -FANCJ axis mediates the restart of DNA replication after fork stalling at cotranscriptional G4/R-loops. Science advances 2024-02-14 [PMID: 38324687]
• Panneerselvam Jayabal, Xiuye Ma, Yuzuru Shiio Roles of USP1 in Ewing sarcoma Genes & Cancer 2024-01-01 [PMID: 38323120]
• Alberto Sogari, Emanuele Rovera, Gaia Grasso, Elisa Mariella, Nicole Megan Reilly, Simona Lamba, Gianluca Mauri, Erika Durinikova, Pietro Paolo Vitiello, Annalisa Lorenzato, Marco Avolio, Eleonora Piumatti, Emanuela Bonoldi, Maria Costanza Aquilano, Sabrina Arena, Andrea Sartore-Bianchi, Salvatore Siena, Livio Trusolino, Manuela Donalisio, Mariangela Russo, Federica Di Nicolantonio, David Lembo, Alberto Bardelli Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. Cell reports. Medicine 2024-02-23 [PMID: 38228147]
• Ramanagoudr-Bhojappa R, Tryon R, Lach FP et Al. FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia Blood Adv 2024-01-10 [PMID: 38191666]
• Peake JD, Horne KI, Noguchi C et al. The p53 DNA damage response and Fanconi anemia DNA repair pathway protect against acetaldehyde-induced replication stress in esophageal keratinocytes Cell cycle (Georgetown, Tex.) 2023-09-25 [PMID: 37749911]
• Tsui V, Lyu R, Novakovic S et al. Fancm has dual roles in the limiting of meiotic crossovers and germ cell maintenance in mammals Cell Genomics 2023-06-01 [PMID: 37601968] (Immunocytochemistry/ Immunofluorescence)
• Hoffman TE, Nangia V, Ill CR et al. Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles Science signaling 2023-08-01 [PMID: 37527351]
• Stok C, Tsaridou S, van den Tempel N et al. FIRRM/C1orf112 is synthetic lethal with PICH and mediates RAD51 dynamics Cell reports 2023-06-21 [PMID: 37347663] (WB, ICC/IF, Human)
  
  Details:
  Dilution: 1:200; HAP1 Cells
• Barreto-Galvez A, Niljikar M, Gagliardi J et al. Acetyl transferase EP300 deficiency leads to chronic replication stress mediated by defective fork protection at stalled replication forks bioRxiv : the preprint server for biology 2023-04-29 [PMID: 37163075] (Human)
  
  Details:
  Used in Mitotic DNA Synthesis (MiDAS); Dilution: 1:1000
• Blaize JL, Noori BM, Hunter KP et al. Differential Regulation of Retinoic Acid Metabolism in Fanconi Anemia bioRxiv : the preprint server for biology 2023-04-27 [PMID: 37066159] (ICC/IF, WB, Human)
• Moore CE, Yalcindag SE, Czeladko H et al. RFWD3 promotes ZRANB3 recruitment to regulate the remodeling of stalled replication forks The Journal of cell biology 2023-05-01 [PMID: 37036693] (WB)
• Andrs M, Stoy H, Boleslavska B et al. Excessive reactive oxygen species induce transcription-dependent replication stress Nature communications 2023-03-30 [PMID: 36997515] (WB, Human)
  
  Details:
  Dilution used in WB 1:1000
• Garribba L, De Feudis G, Martis V et al. Short-term molecular consequences of chromosome mis-segregation for genome stability Nature communications 2023-03-11 [PMID: 36906648] (ICC/IF, Human)
  
  Details:
  Dilution used in ICC/IF 1:200
• Jiang H, Kong N, Liu Z et al. Human Endonuclease ANKLE1 Localizes at the Midbody and Processes Chromatin Bridges to Prevent DNA Damage and cGAS-STING Activation Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023-02-24 [PMID: 36825683] (ICC/IF, Human)
  
  Details:
  Dilution used in ICC/IF 1:1000
• Wu W, Barwacz SA, Bhowmick R et Al. Mitotic DNA synthesis in response to replication stress requires the sequential action of DNA polymerases zeta and delta in human cells Nat Commun 2023-02-09 [PMID: 36759509] (Western Blot)
• Benitez A, Sebald M, Kanagaraj R, Rodrigo-Brenni MC et Al. GEN1 promotes common fragile site expression Cell Rep 2023-02-02 [PMID: 36729836]
• Gao Y, Guitton-Sert L, Dessapt J et Al. A CRISPR-Cas9 screen identifies EXO1 as a formaldehyde resistance gene Nat Commun 2023-01-24 [PMID: 36693839] (Western Blot)
• Chung HJ, Lee JR, Kim TM et al. ZNF212 promotes genomic integrity through direct interaction with TRAIP Nucleic acids research 2023-01-25 [PMID: 36594163] (WB, Mouse)
  
  Details:
  See supplemental figure S7
• BOhly N, Schmidt AK, Zhang X et al. Increased replication origin firing links replication stress to whole chromosomal instability in human cancer Cell reports 2022-12-13 [PMID: 36516748] (ICC/IF, Human)
  
  Details:
  Dilution used in ICC 1:500
• Li N, Xu Y, Chen H et al. NEIL3 contributes to the Fanconi anemia/BRCA pathway by promoting the downstream double-strand break repair step Cell reports 2022-11-08 [PMID: 36351389] (ICC/IF, Human)
• Heijink AM, Stok C, Porubsky D et al. Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51 Nature communications 2022-11-07 [PMID: 36344511] (ICC/IF, Human)
  
  Details:
  Dilution used in ICC 1:1000
• Zheng C, Ren Z, Chen H et al. FANCD2 promotes the malignant behavior of endometrial cancer cells and its prognostic value Experimental cell research 2022-10-15 [PMID: 36257352] (KD, IF/IHC, WB, Human)
• Sun R, Wei T, Ding D et Al. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer Proc Natl Acad Sci U S A 2022-09-21 [PMID: 36129942] (Chromatin Immunoprecipitation, Immunoprecipitation)
• S Gemble, R Wardenaar, K Keuper, N Srivastava, M Nano, AS Macé, AE Tijhuis, SV Bernhard, DCJ Spierings, A Simon, O Goundiam, H Hochegger, M Piel, F Foijer, Z Storchová, R Basto Genetic instability from a single S phase after whole-genome duplication Nature, 2022-03-30;604(7904):146-151. 2022-03-30 [PMID: 35355016]
• Kolinjivadi AM, Sankar H, Choudhary R et al. The H. pylori CagA Oncoprotein Induces DNA Double Strand Breaks through Fanconi Anemia Pathway Downregulation and Replication Fork Collapse International journal of molecular sciences 2022-01-31 [PMID: 35163588] (WB)
• Ruggiano A, Vaz B, Kilgas S et al. The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability Cell reports 2021-12-07 [PMID: 34879279]
• Fierheller CT, Guitton-Sert L, Alenezi WM et al. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene Genome medicine 2021-12-03 [PMID: 34861889] (WB, ICC/IF, Human)
• Katsuki Y, Abe M, Park SY Et al. RNF168 E3 ligase participates in ubiquitin signaling and recruitment of SLX4 during DNA crosslink repair Cell reports 2021-10-26 [PMID: 34706224] (ICC/IF, Human)
• Adeyemi RO, Willis NA, Elia AEH Et al. The Protexin complex counters resection on stalled forks to promote homologous recombination and crosslink repair Molecular cell 2021-09-28 [PMID: 34597596]
• GonzAlez-Acosta D, Blanco-Romero E, Ubieto-Capella P et al. PrimPol-mediated repriming facilitates replication traverse of DNA interstrand crosslinks The EMBO journal 2021-06-15 [PMID: 34128550] (WB)
• Fang X, Dai E, Bai L et al. The HMGB1-AGER-STING1 pathway mediates the sterile inflammatory response to alkaliptosis Biochemical and biophysical research communications 2021-06-30 [PMID: 33992959]
• Duan W, Tang S, Gao L et al. MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers Scientific reports 2021-02-24 [PMID: 33627769] (IHC-P, WB, Human)
• Jones MJK, Gelot C, Munk S et al. Human DDK rescues stalled forks and counteracts checkpoint inhibition at unfired origins to complete DNA replication Molecular cell 2021-02-04 [PMID: 33545059]
• Fernandes P, Miotto B, Saint-Ruf C et al. FANCD2 tunes the UPR preventing mitochondrial stress-induced common fragile site instability. bioRxiv 2019-10-18 [PMID: 33514811] (Chemotaxis, Human)
• Ishimoto R, Tsuzuki Y, Matsumura T, et al. SLX4-XPF mediates DNA damage responses to replication stress induced by DNA-protein interactions The Journal of cell biology 2021-01-04 [PMID: 33347546]
• Calzetta NL, Gonzalez Besteiro MA, Gottifredi V Mus81-Eme1-dependent aberrant processing of DNA replication intermediates in mitosis impairs genome integrity Science advances 2020-12-01 [PMID: 33298441] (ICC/IF, Human)
• Ruiz-Torres S, Brusadelli MG, Witte DP et al. Inherited DNA Repair Defects Disrupt the Structure and Function of Human Skin Cell Stem Cell 2020-11-12 [PMID: 33232662] (WB, ICC/IF, Human)
  
  Details:
  Human epidermal skin progenitor cells, skin keratinocytes, oral kertinocytes underwent Western blot analysis. Immunofluorescence analysis was performed on human epidermal skin progenitor cells treated with DOX.
• Lach FP, Singh S, Rickman KA et al. Esophageal Cancer as initial presentation of Fanconi anemia in patients with a hypomorphic FANCA variant Cold Spring Harb Mol Case Stud 2020-11-10 [PMID: 33172906] (WB, Human)
  
  Details:
  Western blot analysis performed on human fibroblasts transfected with lentivirus.
• Watts LP, Natsume T, Saito Y et al. The RIF1-long splice variant promotes G1 phase 53BP1 nuclear bodies to protect against replication stress Elife 2020-11-03 [PMID: 33141022] (ICC/IF, Human)
• Ma C, Hokutan K, Shen Y et al. TFG-maintaining stability of overlooked FANCD2 confers early DNA-damage response Elife 2020-10-19 [PMID: 33099537]
• Young SJ, Sebald M, Shah Punatar R et al. MutS beta Stimulates Holliday Junction Resolution by the SMX Complex Cell Rep 2020-10-20 [PMID: 33086055] (ICC/IF)
• Gemble S, Amor-Gueret M Identification and Analysis of Different Types of UFBs Methods Mol. Biol. 2020-08-26 [PMID: 32840780]
• Olivieri M, Cho T, Alvarez-QuilOn A et al. A Genetic Map of the Response to DNA Damage in Human Cells Cell 2020-07-23 [PMID: 32649862] (KO, WB, Human)
• Brannvoll A, Xue X, Kwon Y et al. The ZGRF1 Helicase Promotes Recombinational Repair of Replication-Blocking DNA Damage in Human Cells Cell Rep 2020-07-07 [PMID: 32640219] (WB, ICC/IF, Human)
• Kono T, Hoover P, Poropatich K et al. Activation of DNA damage repair factors in HPV positive oropharyngeal cancers Virology 2020-01-01 [PMID: 32560902] (IHC-P, Human)
• Gemble S, Buhagiar-LabarchEde G, Onclercq-Delic R et al. Topoisomerase II alpha prevents ultrafine anaphase bridges by two mechanisms Open Biol 2020-05-01 [PMID: 32400307] (ICC/IF, Human)
• Rickman KA, Noonan R, Lach FP et al. Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand crosslinks Genes Dev 2020-05-02 [PMID: 32354836]
• Xing M, Zhang F, Liao H et al. Replication Stress Induces ATR/CHK1-Dependent Nonrandom Segregation of Damaged Chromosomes Mol. Cell 2020-04-22 [PMID: 32353258]
• Kreutmair S, Erlacher M, Andrieux G et al. Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure J. Clin. Invest. 2020-06-01 [PMID: 32338640] (ICC/IF, IHC-P, Mouse, Human)
• Shao X, Joergensen AM, Howlett NG et al. A distinct role for recombination repair factors in an early cellular response to transcription-replication conflicts Nucleic Acids Res. 2020-04-24 [PMID: 32329774] (ICC/IF, Avian)
• Miller HE, Gorthi A, Bassani N et al. Reconstruction of Ewing Sarcoma Developmental Context from Mass-Scale Transcriptomics Reveals Characteristics of EWSR1-FLI1 Permissibility Cancers (Basel) 2020-04-11 [PMID: 32290418] (WB, Human)
• Cai MY, Dunn CE, Chen W et al. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection Cell Rep 2020-02-18 [PMID: 32075772] (WB, Human)
• Yang Y, Guo T, Liu R et al. FANCL gene mutations in premature ovarian insufficiency Hum. Mutat. 2020-02-12 [PMID: 32048394] (WB, Human)
• Ardeljan D, Steranka JP, Liu C et al. Cell fitness screens reveal a conflict between LINE-1 retrotransposition and DNA replication Nat. Struct. Mol. Biol. 2020-02-01 [PMID: 32042151] (WB)
• Li N, Wang J, Wallace SS et al. Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair Nucleic Acids Res. 2020-01-25 [PMID: 31980815] (WB, Human)
• Chappidi N, Nascakova Z, Boleslavska B et al. Fork Cleavage-Religation Cycle and Active Transcription Mediate Replication Restart after Fork Stalling at Co-transcriptional R-Loops Mol. Cell 2019-11-13 [PMID: 31759821]
• Achuthankutty D, Thakur RS, Haahr P et al. Regulation of ETAA1-mediated ATR activation couples DNA replication fidelity and genome stability J. Cell Biol. 2019-10-15 [PMID: 31615875]
• Bishop DK Non-enzymatic roles of human RAD51 at stalled replication forks. Mason JM, Chan YL, Weichselbaum RW et al. Nat Commun. [PMID: 31562309] (WB, Human)
• Sonneville R, Bhowmick R, Hoffmann S et al. TRAIP drives replisome disassembly and mitotic DNA repair synthesis at sites of incomplete DNA replication Elife [PMID: 31545170] (ICC/IF)
  
  Details:
  Used at 1:400 for immunofluorescence.
• Chang EY, Tsai S, Aristizabal MJ et al. MRE11-RAD50-NBS1 promotes Fanconi Anemia R-loop suppression at transcription-replication conflicts Nat Commun 2019-09-19 [PMID: 31537797] (WB)
• Bi J, Areecheewakul S, Li Y et al. MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy Gynecol. Oncol. 2019-08-30 [PMID: 31477281] (WB, Human)
• Andreev V, Hristova R, Asparuhova M et al. Mammalian INO80 chromatin remodeler cooperates with FANCM to mediate DNA interstrand crosslink-induced checkpoint activation and repair DNA Repair (Amst.) 2019-02-01 [PMID: 30606611] (ICC/IF, Human)
• Chang E, Wells J, Tsai S et al. MRE11-RAD50-NBS1 activates Fanconi Anemia R-loop suppression at transcription-replication conflicts. Oncotarget. (WB, Human)
• Vilfranc CL Elucidating the Role of BRUCE in Chronic Liver Disease Pathogenesis Thesis 2021-01-01 (WB, ICC/IF)
• Hermanowski H, Huebert B, Aldrighetti C et al. Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma bioRxiv 2020-07-01 (ICC/IF, Human)
• Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene medRxiv 2020-01-01 (WB, Human)
• Tian C, Hoffman Te, Jacobsen Nk, Spencer Sl Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cells bioRxiv 2020-01-01
• Fragkos M, Barra V, Egger T et al. Dicer prevents genome instability in response to replication stress Oncotarget 2019-07-08 [PMID: 31320994] (WB, Human)
• Tacconi Eliana Mc, Badie Sophie, De Gregoriis Giuliana et al. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. Embo Molecular Medicine 2019-07-01 [PMID: 31273933] (WB)
• Pladevall-Morera D, Munk S, Ingham A et al. Proteomic characterization of chromosomal common fragile site (CFS)-associated proteins uncovers ATRX as a regulator of CFS stability Nucleic Acids Res. 2019-06-10 [PMID: 31180492] (IF, Human)
• Tacconi EM, Badie S, De Gregoriis G, Reislander T et al. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance EMBO Mol Med 2019-05-24 [PMID: 31127019] (WB, Human)
• Paquin KL, Mamrak NE, Garzon JL et al. FANCD2 Binding to H4K20me2 via a Methyl-Binding Domain Is Essential for Efficient DNA Cross-Link Repair Mol. Cell. Biol. 2019-08-01 [PMID: 31085681] (WB, Human)
• Huang J, Zhang J, Bellani MA et al. Remodeling of Interstrand Crosslink Proximal Replisomes Is Dependent on ATR, FANCM, and FANCD2 Cell Rep 2019-05-07 [PMID: 31067464] (WB, Mouse)
• Ramanagoudr-Bhojappa R, Carrington B, Ramaswami M et al. Multiplexed CRISPR/Cas9-mediated knockout of 19 Fanconi anemia pathway genes in zebrafish revealed their roles in growth, sexual development and fertility PLoS Genet. 2018-12-12 [PMID: 30540754] (WB, Zebrafish)
• Fernandez-Vidal A, Arnaud LC, Maumus M et al. Exposure to the fungicide captan induces DNA base alterations and replicative stress in mammalian cells. Environ. Mol. Mutagen. 2018-11-24 [PMID: 30471166]
• Balcerek J, Jiang J, Li Y et al. Lnk/Sh2b3 deficiency restores hematopoietic stem cell function and genome integrity in Fancd2 deficient Fanconi anemia. Nat Commun 2018-09-25 [PMID: 30254368] (WB, Mouse)
• Andrews AM, McCartneY HJ, Errington TM et al. A senataxin-associated exonuclease SAN1 is required for resistance to DNA interstrand cross-links. Nat Commun. 2018-07-03 [PMID: 29968717] (WB, Human)
• Higgs MR, Sato K, Reynolds JJ et al. Histone Methylation by SETD1A Protects Nascent DNA through the Nucleosome Chaperone Activity of FANCD2 Mol. Cell 2018-06-07 [PMID: 29937342] (Human)
• Hao Yin, Hui Ma, Sajjad Hussain, Huan Zhang, Xuefeng Xie, Long Jiang, Xiaohua Jiang, Furhan Iqbal, Ihtisham Bukhari, Hanwei Jiang, Asim Ali, Liangwen Zhong, Tao Li, Suixing Fan, Beibei Zhang, Jianing Gao, Yang Li, Jabeen Nazish, Teka Khan, Manan Khan, Muhammad Zubair, Qiaomei Hao, Hui Fang, Jun Huang, Mahmoud Huleihel, Jiahao Sha, Tej K. Pandita, Yuanwei Zhang, Qinghua Shi A homozygous FANCM frameshift pathogenic variant causes male infertility Genetics in Medicine 2018-06-12 [PMID: 29895858]
• Tremblay CS, Huang FF, Levesque G, Carreau M. Fanconi anemia core complex-dependent HES1 mono-ubiquitination regulates its transcriptional activity. BMC Res Notes. 2018-02-20 [PMID: 29463306] (Human)
• Kim J, Sturgill D, Sebastian R et al. Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions Mol. Cell [PMID: 29249653] (ICC/IF, Human)
• Asur RS, Kimble DC, Lach FP et al. Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype. Mol Genet Genomic Med 2017-11-30 [PMID: 29193904] (ICC/IF, WB, Human)
• Hooks KB, Audoux J, Fazli H et al. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma Hepatology. 2017-11-20 [PMID: 29152775] (WB, ICC/IF, Human)
• Sakasai R, Isono M, Wakasugi M et al. Aquarius is required for proper CtIP expression and homologous recombination repair. Sci Rep. 2017-10-23 [PMID: 29061988] (WB, Human)
• Porro A, Berti M, Pizzolato J et al. FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2. Nat Commun. 2017-10-20 [PMID: 29051491] (WB, Human)
• Chang EY, Novoa CA, Aristizabal MJ et al. RECQ-like helicases Sgs1 and BLM regulate R-loop-associated genome instability. J. Cell Biol. 2017-10-17 [PMID: 29042409] (Human)
• Leick L. Analysis of molecular components, causing Fanconi Anemia-like phenotype in HPV-16 infected Head and Neck Squamous Cell Carcinomas. Thesis 2017-01-01 (WB)
• Vierra DA, Garzon JL, Rego MA et al. Modulation of the Fanconi anemia pathway via chemically induced changes in chromatin structure Oncotarget. 2017-09-29 [PMID: 29100324] (WB, ICC/IF, Human)
• Preiss MR, Cournoyer E, Paquin KL et al. Tuning the Multifunctionality of Iron Oxide Nanoparticles Using Self-Assembled Mixed Lipid Layers. Bioconjug. Chem. 2017-10-30 [PMID: 29035511] (WB)
• Moriel-Carretero M, Ovejero S, Gerus-Durand M et al. Fanconi anemia FANCD2 and FANCI proteins regulate the nuclear dynamics of splicing factors. J. Cell Biol. 2017-10-13 [PMID: 29030393] (Human)
• Bou Samra E, Buhagiar-Labarchede G, Machon C et al. A role for Tau protein in maintaining ribosomal DNA stability and cytidine deaminase-deficient cell survival. Nat Commun 2017-09-25 [PMID: 28947735] (ICC/IF, Human)
• Feng W, Jasin M. BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination Nat Commun 2017-09-13 [PMID: 28904335] (ICC/IF, Human)
• Wilkes David C, Sailer Verena, Xue Hui et al. A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harbor Molecular Case Studies 2017-05-03 [PMID: 28864460] (ICC/IF, Human)
• Tacconi EM, Lai X, Folio C et al. BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity EMBO Mol Med 2017-07-20 [PMID: 28729482] (WB, Mouse)
• Marchesini M, Ogoti Y, Fiorini E et al. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma Cancer Cell 2017-07-10 [PMID: 28669490] (Human)
• Niraj J, Caron MC, Drapeau K et al. The identification of FANCD2 DNA binding domains reveals nuclear localization sequences Nucleic Acids Res. 2017-06-28 [PMID: 28666371] (WB, Human)
• Di Marco S, Hasanova Z et al. RECQ5 Helicase Cooperates with MUS81 Endonuclease in Processing Stalled Replication Forks at Common Fragile Sites during Mitosis. Mol Cell 2017-01-06 [PMID: 28575661] (ICC/IF, Human)
• Jiang J, Bellani M, Li L et al. Arsenite Binds to the RING Finger Domain of FANCL E3 Ubiquitin Ligase and Inhibits DNA Interstrand Cross-link Repair. ACS Chem. Biol. 2017-05-23 [PMID: 28535027]
• Ren L, Chen L et al. Potential biomarkers of DNA replication stress in cancer. Oncotarget 2017-06-06 [PMID: 28445142] (IF/IHC, Human)
• Bharathan SP, Nandy K, Palani D et al. Generation of an induced pluripotent stem cell line that mimics the disease phenotypes from a patient with Fanconi anemia by conditional complementation. Stem Cell Research. 2017-02-22 [PMID: 28395741] (ICC/IF, Human)
• Zhang T, Du W et al. Fancd2 in vivo interaction network reveals a non-canonical role in mitochondrial function. Sci Rep 2017-05-04 [PMID: 28378742] (WB, Mouse)
• Spriggs CC, Laimins LA. FANCD2 Binds Human Papillomavirus Genomes and Associates with a Distinct Set of DNA Repair Proteins to Regulate Viral Replication. MBio. 2017-02-14 [PMID: 28196964]
• Chun MJ, Choi H, Jun DW et al. Fanconi anemia protein FANCD2 is activated by AICAR, a modulator of AMPK and cellular energy metabolism. FEBS OpenBio. 2017-01-09 [PMID: 28174693] (WB, ICC/IF, Human)
• Lv Z, Rickman KA, Yuan L et al. S. pombe Uba1-Ubc15 Structure Reveals a Novel Regulatory Mechanism of Ubiquitin E2 Activity. Mol. Cell. 2017-02-16 [PMID: 28162934] (WB)
• Johnson SF, Cruz C, Greifenberg AK et al. CDK12 INHIBITION REVERSES DE NOVO AND ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA WILD-TYPE AND MUTATED MODELS OF TRIPLE-NEGATIVE BREAST CANCER Cell Rep. 2016-11-21 [PMID: 27880910] (WB, Human)
• Vuono EA, Mukherjee A, Vierra DA et al. The PTEN phosphatase functions cooperatively with the Fanconi anemia proteins in DNA crosslink repair. Sci Rep. 2016-11-07 [PMID: 27819275] (Human)
• Bezine E, Malaise Y, Loeuillet A et al. Cell resistance to the Cytolethal Distending Toxin involves an association of DNA repair mechanisms. Sci Rep 2016-10-24 [PMID: 27775089] (WB, Human)
• Alavattam KG, Kato Y, Sin HS et al. Elucidation of the Fanconi Anemia Protein Network in Meoisis and Its Function in the Regulation of Histone Modifications. Cell Rep 2016-10-18 [PMID: 27760317] (WB, Human)
• Sato K, Shimomuki M, Katsuki Y et al. FANCI-FANCD2 stabilizes the RAD51-DNA complex by binding RAD51 and protects the 5'-DNA end. Nucleic Acids Res. 2016-09-30 [PMID: 27694619] (RNAi, WB, Human)
• Fu C, Begum K, Jordan PW et al. Dearth and Delayed Maturation of Testicular Germ Cells in Fanconi Anemia E Mutant Male Mice. PLoS One 2016-08-03 [PMID: 27486799] (IF/IHC)
• Root H, Larsen A, Komosa M et al. FANCD2 limits BLM-dependent telomere instability in the alternative lengthening of telomeres pathway Hum. Mol. Genet. 2016-07-17 [PMID: 27427384]
• Chun MJ, Hwang SK, Kim HG et al. Aurora A kinase is required for activation of the Fanconi anemia/BRCA pathway upon DNA damage. FEBS Open Bio. 2016-05-19 [PMID: 27398318] (WB, ICC/IF, Human)
• Michl J, Zimmer J, Buffa FM et al. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat Struct Mol Biol 2016-08-01 [PMID: 27322732] (WB, Human)
• Kais Z, Rondinelli B, Holmes A et al. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. Cell Rep 2016-06-14 [PMID: 27264184] (WB)
• Maeda J, Froning CE, Brents CA et al. Intrinsic Radiosensitivity and Cellular Characterization of 27 Canine Cancer Cell Lines. PLoS ONE 2016-06-04 [PMID: 27257868] (WB, Canine)
• Cosetta Bertoli, Anna E. Herlihy, Betheney R. Pennycook, Janos Kriston-Vizi, Robertus A.M. de Bruin Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage Cell Reports 2016-05-05 [PMID: 27160911]
• Wang F, Gao C, Lu J et al. Leukemic survival factor SALL4 contributes to defective DNA damage repair. Oncogene. 2016-05-02 [PMID: 27132514] (WB, Human)
• Panneerselvam J, Wang H, Zhang J et al. BLM promotes the activation of Fanconi Anemia signaling pathway. Oncotarget. 2016-04-12 [PMID: 27083049] (ICC/IF, WB, Human)
• Minocherhomji S, Ying S, Bjerregaard VA et al. Replication stress activates DNA repair synthesis in mitosis. Nature 2015-12-02 [PMID: 26633632] (WB, ICC/IF, Human)
• Bouffard F, Plourde K, Belanger S et al. Analysis of a FANCE Splice Isoform in Regard to DNA Repair. J. Mol. Biol. 2015-08-12 [PMID: 26277624] (WB, Human)
• Stoepker C, Ameziane N, van der Lelij P et al. Defects in the fanconi anemia pathway and chromatid cohesion in head-and-neck cancer Cancer Res. 2015-06-29 [PMID: 26122845] (ICC/IF, WB, Human)
• Rickman KA, Lach FP, Abhyankar A et al. Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia. Cell Rep 2015-07-07 [PMID: 26119737]
• Zhu J, Su F, Mukherjee S et al. FANCD2 influences replication fork processes and genome stability in response to clustered DSBs. Cell Cycle 2015-01-01 [PMID: 26083937] (WB)
• Zhang T, Wilson AF, Ali AM et al. Loss of Faap20 Causes Hematopoietic Stem and Progenitor Cell Depletion in Mice Under Genotoxic Stress Stem Cells 2015-04-27 [PMID: 25917546]
• Olivieri, M, M Charting the genetic architecture of the DNA damage response in human cells Thesis 2022-01-01 (WB, Human)
• Stok C Mitotic processing of DNA replication and repair intermediates in cancer University of Groningen 2023-05-23 (ICC/IF, Human)
• Oka Y, Bekker-Jensen S, Mailand N. Ubiquitin-like protein UBL5 promotes the functional integrity of the Fanconi anemia pathway EMBO J. 2015-04-09 [PMID: 25862789] (WB, Human)
• Xie J, Kim H, Moreau LA et al. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. J. Clin. Invest. 2015-04-01 [PMID: 25751062] (ICC/IF, Human)
• Brem R, Zhang X, Xu YZ et al. UVA Photoactivation of DNA Containing Halogenated Thiopyrimidines Induces Cytotoxic DNA lesions Journal of Photochemistry and Photobiology B: Biology. 2015-02-20 [PMID: 25747491] (WB, Human)
  
  Details:
  FANCD2 antibody was used in WB application for the detection of FANCD2 activation in 50ug lysates of HeLa cells which were previously treated with 25 ?M SIdU or SBrdU for 24 hours followed by UVA irradiation (lysates prepared 2 hours after the radiation). The samples showed doublet bands for FANCD2 which represented the FANCD2's un-modified form/lower band and its monoubiquitinated form/top band (Fig 2C).
• Aarts M, Bajrami I, Herrera-Abreu MT et al. Functional genetic screen identifies increased sensitivity to WEE1 inhibition in cells with defects in Fanconi Anaemia and HR pathways Mol. Cancer Ther. 2015-02-11 [PMID: 25673822] (WB, Human)
• Stoepker C, Faramarz A, Rooimans MA, van Mil SE. DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity. DNA Repair. 2014-12-24 [PMID: 25583207] (ICC/IF, Human)
  
  Details:
  FANCD2 antibody used for ICC-IF in experiments involving head and neck tumor cell lines (VU-SCC-1131 (FANCC-deficient), VU-SCC-1365 (FANCA-deficient) and VU-SCC-1604 (FANCL-deficient)) derived from FA patients (Fig. 5D).
• Duan W, Gao L, Aguila B et al. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol. 2015-01-08 [PMID: 25566506] (WB, IHC-P, Human)
  
  Details:
  The paraffin-embedded human lung tumor tissue sections stained with FANCD2 antibody and analyzed by FATSI method. The FANCD2 antibody was also used for WB analysis on lung cancer cells.
• Bursomanno S, Beli P, Khan AM et al. Proteome-wide analysis of SUMO2 targets in response to pathological DNA replication stress in human cells. DNA Repair (Amst). 2014-11-25 [PMID: 25497329] (WB, Human)
• Zhu B, Yan K, Li L et al. K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks. Oncogene. 2014-08-18 [PMID: 25132264]
• Chlon TM, Hoskins EE, Mayhew CN et al. High risk HPV E6 protein promotes reprogramming of Fanconi Anemia patient cells through repression of p53 but does not allow for sustained growth of iPSC. J. Virol. 2014-07-16 [PMID: 25031356] (WB, Human)
  
  Details:
  FANCD2 antibody used for WB in FA patients-derived cell (FIG 2B) and on induced pluripotent stem cells/iPSC lines as well as parental keratinocytes from patients FA-A2 to -4 treated with 1 mM hydroxyurea (FIG 5J).
• Silva Barbara Alcaraz, Stambaugh Jessica R, Yokomori Kyoko et al. DNA damage to a single chromosome end delays anaphase onset. J Biol Chem. 2014-08-15 [PMID: 24982423]
• Huang Y, Leung JW, Lowery M et al. Modularized functions of the Fanconi anemia core complex. Cell Rep 2014-06-26 [PMID: 24910428]
• Sarbajna Shriparna, Davies Derek, West Stephen C. Roles of SLX1-SLX4, MUS81-EME1, and GEN1 in avoiding genome instability and mitotic catastrophe. Genes Dev. 2014-05-15 [PMID: 24831703] (ICC/IF, Human)
• Panneerselvam J, Pickering A, Han B et al. Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate. Oncotarget 2014-07-15 [PMID: 24658369] (WB, Human)
  
  Details:
  MCM6 antibody used for WB on several experiments involving CRL-1790 and HEK293T cells.
• Huard CC, Tremblay CS, Magron A, Carreau M. The Fanconi anemia pathway has a dual function in Dickkopf-1 transcriptional repression. Proc. Natl. Acad. Sci. U.S.A. 2014-02-12 [PMID: 24469828] (WB, Human)
• Boisvert RA, Rego MA, Azzinaro PA et al. Coordinate Nuclear Targeting of the FANCD2 and FANCI Proteins via a FANCD2 Nuclear Localization Signal. PLoS One. 2013-11-21 [PMID: 24278431] (ICC/IF, WB, Human)
• Figueiredo N, Chora A, Raquel H et al. Anthracyclines Induce DNA Damage Response-Mediated Protection against Severe Sepsis. Immunity. 2013-11-14 [PMID: 24184056] (WB, Human)
• Wha Jun D, Hwang M, Kim HJ et al. Ouabain, a Cardiac Glycoside, Inhibits the Fanconi Anemia/BRCA Pathway Activated by DNA Interstrand Cross-Linking Agents. PLoS One. 2013-10-04 [PMID: 24124520] (WB, Human)
• Wang Y, Han X, Wu F et al. Structure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage response. Cell Res. 2013-10-01 [PMID: 23999858] (WB, Human)
• Pfaffle HN, Wang M, Gheorghiu L et al. EGFR activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013-08-21 [PMID: 23966292] (ICC/IF, Human)
• Coulthard R, Deans AJ, Swuec P et al. Architecture and DNA Recognition Elements of the Fanconi Anemia FANCM-FAAP24 Complex. Structure. 2013-09-03 [PMID: 23932590] (WB, Human)
• Mason JM, Das I, Arlt M et al. The SNM1B/APOLLO DNA nuclease functions in resolution of replication stress and maintenance of common fragile site stability. Hum Mol Genet 2013-07-30 [PMID: 23863462] (WB, ICC/IF, Human)
• Ying S, Minocherhomji S, Chan KL et al. MUS81 promotes common fragile site expression. Nat Cell Biol 2013-06-30 [PMID: 23811685] (ICC/IF, Human)
• Tomida J, Itaya A, Shigechi T et al. A novel interplay between the Fanconi anemia core complex and ATR-ATRIP kinase during DNA cross-link repair. Nucleic Acids Res 2013-05-30 [PMID: 23723247] (WB, Human)
• Zhang P, Herbig U, Coffman F, Lambert MW. Non-erythroid alpha spectrin prevents telomere dysfunction after DNA interstrand cross-link damage Nucleic Acids Res 2013-04-09 [PMID: 23571757] (ICC/IF, Human)
• Fu D, Dudimah FD, Zhang J et al. Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA damage. Cell Cycle 2013-03-01 [PMID: 23388460] (WB, Human)
• Wang Y, Leung JW, Jiang Y et al. FANCM and FAAP24 Maintain Genome Stability via Cooperative as Well as Unique Functions. Mol Cell 2013-01-16 [PMID: 23333308] (ICC/IF, WB, Human)
• Gravells P, Hoh L, Solovieva S et al. Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia. Oncogene 2013-01-14 [PMID: 23318456] (WB, Human)
• Bhat A, Andersen PL, Qin Z, Xiao W. Rev3, the catalytic subunit of Polzeta, is required for maintaining fragile site stability in human cells Nucleic Acids Res 2013-01-08 [PMID: 23303771] (ICC/IF, Human)
• Hays LE. Multifunctionality of the FA pathway. Blood 2013-01-03 [PMID: 23287621] (IP, Human)
• Yuce O, West SC. Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response Mol Cell Biol 2013-01-01 [PMID: 23149945] (ICC/IF, Human)
• Duquette ML, Zhu Q, Taylor ER et al. CtIP Is Required to Initiate Replication-Dependent Interstrand Crosslink Repair PLoS Genet 2012-11-01 [PMID: 23144634] (ICC/IF, Human)
• Ogi T, Walker S, Stiff T, Hobson E et al. Identification of the First ATRIP-Deficient Patient and Novel Mutations in ATR Define a Clinical Spectrum for ATR-ATRIP Seckel Syndrome PLoS Genet 2012-11-01 [PMID: 23144622] (WB, Human)
• Kim Y, Spitz GS, Veturi U et al. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4 Blood 2012-10-23 [PMID: 23093618]
• Duan W, Gao L, Zhao W, Leon M et al. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents Transl Res 2012-10-11 [PMID: 23063585] (IF/IHC, ICC/IF, Human)
• Rego MA, Kolling FW 4th, Vuono EA et al. Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein Blood 2012-09-06 [PMID: 22855611]
• Panneerselvam J, Park HK, Zhang J et al. FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer Cell Cycle 2012-08-01 [PMID: 22828653] (WB, ICC/IF, Human)
• Brem R, Karran P. Oxidation-mediated DNA cross-linking contributes to the toxicity of 6-thioguanine in human cells Cancer Res 2012-09-15 [PMID: 22822082] (WB, Human)
• Zhou W, Otto EA, Cluckey A et al. FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet 2012-08-01 [PMID: 22772369]
• Wang Y, Huang JW, Calses P et al. MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition Cancer Res 2012-08-15 [PMID: 22761336] (ICC/IF, Human)
• Ceccaldi R, Parmar K, Mouly E et al. Bone Marrow Failure in Fanconi Anemia Is Triggered by an Exacerbated p53/p21 DNA Damage Response that Impairs Hematopoietic Stem and Progenitor Cells Cell Stem Cell 2012-06-07 [PMID: 22683204] (ICC/IF, WB, Human)
• Hoskins EE, Morreale RJ, Werner SP et al. The Fanconi Anemia Pathway Limits Human Papillomavirus Replication J Virol 2012-08-01 [PMID: 22623785] (WB, Human)
• An JY, Kim E, Zakrzewska A, Yoo YD, Jang JM, Han DH, Lee MJ, Seo JW, Lee YJ, Kim TY, de Rooij DG, Kim BY, Kwon YT. UBR2 of the N-End Rule Pathway Is Required for Chromosome Stability via Histone Ubiquitylation in Spermatocytes and Somatic Cells. PLoS One;7(5):e37414. 2012-01-01 [PMID: 22616001] (ICC/IF, Mouse)
• Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin Mol Cancer 2012-04-26 [PMID: 22537224] (WB, ICC/IF, Human)
• Leung JW, Wang Y, Fong KW et al. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci U S A 2012-03-01 [PMID: 22396592] (WB, ICC/IF, Human)
• Bilardi RA, Kimura KI, Phillips DR, Cutts SM. Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways. Biochem Pharmacol. 2012-02-02 [PMID: 22326903] (ICC/IF, Mouse)
• Jones MJ, Colnaghi L, Huang TT. Dysregulation of DNA polymerase ? recruitment to replication forks results in genomic instability. EMBO J 2011-12-13 [PMID: 22157819] (ICC/IF, Human)
• Hovest MG, Krieg T, Herrmann G. Differential roles for Chk1 and FANCD2 in ATR-mediated signalling for psoralen photoactivation-induced senescence. Exp Dermatol;20(11):883-9. 2011-11-01 [PMID: 21995812] (WB, ICC/IF, Human)
• Le VT, Trilling M, Hengel H. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-alpha signaling. J Virol 2011-12-01 [PMID: 21976655] (WB)
• Lu WT, Lemonidis K, Drayton RM, Nouspikel T et al. The Fanconi anemia pathway is downregulated upon macrophage differentiation through two distinct mechanisms. Cell Cycle 2011-10-01 [PMID: 21926477] (Human)
• Jacome A, Fernandez-Capetillo O. Lac operator repeats generate a traceable fragile site in mammalian cells. EMBO Rep. 2011-08-12 [PMID: 21836640] (ICC/IF, Mouse)
• Puspasari N, Rowley SM, Gordon L et al. Long range regulation of human FXN gene expression. PLoS One 2011-01-01 [PMID: 21760943] (ICC/IF)
• Brem R, Daehn I, Karran P. Efficient DNA interstrand crosslinking by 6-thioguanine and UVA radiation. DNA Repair (Amst);10(8):869-76. 2011-08-15 [PMID: 21723207] (WB, Human)
• Rego MA, Harney JA, Mauro M et al. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 2012-01-19 [PMID: 21685936] (ICC/IF, WB, Human)
• Kavanaugh GM, Wise-Draper TM, Morreale RJ et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res;39(17):7465-76. 2011-09-01 [PMID: 21653549] (ICC/IF, Human)
• Mason JM, Sekiguchi JM. SNM1B/APOLLO functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks. Hum Mol Genet. 2011-04-08 [PMID: 21478198] (WB, ICC/IF, Human)
• Baldeyron C, Soria G, Roche D et al. HP1alpha recruitment to DNA damage by p150CAF-1 promotes homologous recombination repair. J Cell Biol 2011-04-01 [PMID: 21464229] (ICC/IF, WB, Mouse, Human)
• Wright JW, Pejovic T, Jurevic L et al. Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement. Hum Reprod. 2011-06-01 [PMID: 21421661] (IHC-P, Primate)
• Stoepker C, Hain K, Schuster B et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011-02-01 [PMID: 21240277] (ICC/IF, Human)
• Kim Y, Lach FP, Desetty R et al. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011-02-01 [PMID: 21240275] (WB, Human)
• Ceccaldi R, Briot D, Larghero J, et al. Spontaneous abrogation of the G2DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients J Clin Invest 2011-01-01 [PMID: 21183791] (WB, Human)
• Ellwood SR, Liu Z, Syme RA et al. A first genome assembly of the barley fungal pathogen Pyrenophora teres f. teres. Genome Biol 2010-01-01 [PMID: 21067574]
• Colnaghi L, Jones MJ, Cotto-Rios XM et al. Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair. Blood 2011-02-17 [PMID: 20971953] (ICC/IF, Human)
• Fairclough SR, Dayel MJ, King N. Multicellular development in a choanoflagellate. Curr Biol 2010-10-26 [PMID: 20971426] (ICC/IF)
• Rivera T, Losada A. Recycling cohesin rings by deacetylation. Mol Cell 2010-09-10 [PMID: 20832715]
• Smogorzewska A, Desetty R, Saito TT et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 2010-07-09 [PMID: 20603073]
• MacKay C, Declais AC, Lundin C et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 2010-07-09 [PMID: 20603015] (ICC/IF, Human)
• Puri S, Hohle TH, O'Brian MR. Control of bacterial iron homeostasis by manganese. Proc Natl Acad Sci U S A 2010-06-08 [PMID: 20498065] (ICC/IF)
• Lyakhovich A, Surralles J. Constitutive activation of caspase-3 and Poly ADP ribose polymerase cleavage in fanconi anemia cells. Mol Cancer Res;8(1):46-56. 2010-01-01 [PMID: 20068062] (WB, Human)
• Deans AJ, West SC., et al. FANCM Connects the Genome Instability Disorders Bloom's Syndrome and Fanconi Anemia. Mol Cell 2009-12-25 [PMID: 20064461] (WB, Human)
• Bhagwat N, Olsen AL, Wang AT et al. XPF-ERCC1 participates in the Fanconi anemia pathway of crosslink repair. Mol Cell Biol :MCB.00086-00009. 2009-01-01 [PMID: 19805513] (ICC/IF, WB, Human)
• Howlett NG, Harney JA, Rego MA et al. Functional Interaction between the Fanconi Anemia D2 Protein and Proliferating Cell Nuclear Antigen (PCNA) via a Conserved Putative PCNA Interaction Motif. J Biol Chem;284(42):28935-28942. 2009-01-01 [PMID: 19704162] (WB, Human)
• Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009-07-02 [PMID: 19483674] (ICC/IF, Human)
• Tremblay CS, Huang FF, Habi O, Huard CC, Godin C, Levesque G, Carreau M. HES1 is a novel interactor of the Fanconi anemia core complex. Blood. 112(5):2062-70. Epub 2008 Jun 11. Erratum in: Blood. 2009 Oct 29;114(18):3974. 2008-09-01 [PMID: 18550849] (ICC/IF, WB, Human)
• Willers H, Kachnic LA, Luo CM et al. Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 2008-01-01 [PMID: 18483568] (ICC/IF, Human)
• Kolas NK, Chapman JR, Nakada S et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science;318(5856):1637-40. 2007-12-07 [PMID: 18006705]
• Jacquemont, C Taniguchi, T. Proteasome Function Is Required for DNA Damage Response Fanconi Anemia Pathway Activation. Cancer Res; 67: 7395 - 7405. 2007-08-01 [PMID: 17671210] (ICC/IF, Human)
• Collis SJ, Barber LJ, Clark AJ et al. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 2007-04-01 [PMID: 17384638] (WB, Human)
• Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood;109(11):5016-26. 2007-06-01 [PMID: 17327415] (WB, Human)
• Dunn J, Potter M, Rees A, Runger TM. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light. Cancer Res;66(23):11140-7. 2006-12-01 [PMID: 17145857]
• Mukhopadhyay SS, Leung KS, Hicks MJ, Hastings PJ, Youssoufian H, Plon SE. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J Cell Biol;175(2):225-35. 2006-10-23 [PMID: 17060495] (WB, Human)
• Tremblay S, Pintor Dos Reis P, Bradley G, Galloni NN, Perez-Ordonez B, Freeman J, Brown D, Gilbert R, Gullane P, Irish J, Kamel-Reid S. Young patients with oral squamous cell carcinoma: study of the involvement of GSTP1 and deregulation of the Fanconi anemia genes. Arch Otolaryngol Head Neck Surg;132 (9):958-66. 2006-09-01 [PMID: 16982972] (IHC-P, Human)
• Bekker-Jensen, S, Lukas, C, Kitagawa, R, Meler, F, Kastan, M B, Bartek, J, Lukas, J. Spatial organization of the mammalian genome surveillance machinery in response to DNA str breaks, . 173, 195-206. 2006-01-01 [PMID: 16618811] (ICC/IF, Human)
• Stiff T, Reis C, Alderton GK, Woodbine L, O'Driscoll M, Jeggo PA. Nbs1 is required for ATR-dependent phosphorylation events. EMBO J;24(1):199-208. 2005-01-12 [PMID: 15616588] (ICC/IF, Human)
• Demuth I, Digweed M, Concannon P. Human SNM1B is required for normal cellular response to both DNA interstrand crosslink-inducing agents and ionizing radiation. Oncogene 2004-11-11 [PMID: 15467758] (IP, Human)
• Donahue, S et al. A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts. Nucleic Acids Res;32(10):3248-57. 2004-06-15 [PMID: 15199173] (Human)
• Rothfuss, A et al. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol;24(1):123-34. 2004-01-01 [PMID: 14673148] (WB, ICC/IF, Human)
• Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell;3(5):417-20. 2003-05-01 [PMID: 12781358]
• Taniguchi, T et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med;9(5):568-74. 2003-05-01 [PMID: 12692539] (IP, WB, ICC/IF, Human)
• Lensch, MW et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood;102(1):7-16. 2003-07-01 [PMID: 12637330] (WB, Human)
• Sridharan, D et al. Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J Cell Sci;116(Pt 5):823-35. 2003-03-01 [PMID: 12571280] (IP, WB, ICC/IF, Human)
• Taniguchi, T et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood;100(7):2414-20. 2002-10-01 [PMID: 12239151] (ICC/IF, WB, Human)
• Digweed M, Rothe S, Demuth I, Scholz R, Schindler D, Stumm M, Grompe M, Jordan A, Sperling K. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis;23(7):1121-6. 2002-07-01 [PMID: 12117768]
• Yang Y, Kuang Y, Montes De Oca R, Hays T, Moreau L, Lu N, Seed B, D'Andrea AD. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood;98(12):3435-40. 2001-12-01 [PMID: 11719385] (WB, Mouse)
• McMahon, L et al. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links. Biochemistry;40(24):7025-34. 2001-06-19 [PMID: 11401546] (WB, IP, Human)
• Garcia-Higuera, I et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell;7(2):249-62. 2001-02-01 [PMID: 11239454] (WB, ICC/IF, Human)

Reviews for FANCD2 Antibody (NB100-182) (8)

Average Rating: 4.5

(Based on 8 reviews)

We have 8 reviews tested in 4 species: Human, Mouse, Other, humam cell lines.

reviewed by: Verified Customer IF experiment Mouse 01/21/2020

Summary

• Application: Other
• Sample Tested: Mouse embryonic fibroblasts
• Species: Mouse
• Lot: N/A

reviewed by: Verified Customer WB humam cell lines 01/22/2018

Summary

• Application: Western Blot
• Sample Tested: Human Cell lines
• Species: humam cell lines
• Lot: R-5

reviewed by: Lisa Moreau WB Human 12/15/2017

Summary

• Application: Western Blot
• Sample Tested: 20 ug whole cell lysate
• Species: Human
• Lot: R-5

Comments

• Comments: The WB was performed using 3%-8% Gel.

reviewed by: Verified Customer WB Other 12/12/2014

Summary

• Application: Western Blot
• Sample Tested: See PMID 24124520
• Species: Other

reviewed by: Verified Customer IF Other 12/12/2014

Summary

• Application: Immunofluorescence
• Sample Tested: See PMID 24124520
• Species: Other

reviewed by: Verified Customer WB Human 12/12/2014

Summary

• Application: Western Blot
• Sample Tested: See PMID 23318456
• Species: Human

reviewed by: Alan Yueh-Luen WB Human 08/31/2011

Summary

• Application: Western Blot
• Sample Tested: Human Cell Lysate
• Species: Human

reviewed by: Wei-Ting Lu WB Human 02/11/2011

Summary

• Application: Western Blot
• Sample Tested: PD20 cell line (corrected with FancD2)- whole cell extract, Sample Amount: 20 ug / lane
• Species: Human

FAQs for FANCD2 Antibody (NB100-182). (Showing 1 - 3 of 3 FAQs).

1. Which clone is used to produce this antibody? I have some suspicion that it might be the same as the one from Abcam (ab2187). As I want to have two different staining of FANCD2, I would like to be sure that it’s not the same antibody.
   • These are polyclonal antibodies, so there will not be a clone ID associated with them. However, I can tell you that NB100-182 is the same as ab2187.
2. We would like to know if the antibody is specific for isoform a, 1471aa (Q9BXW9) or isoform b, 1451aa (Q9BXW9-2)?
   • This antibody has been generated using human FANCD2 fusion protein (N-terminal fragment) as an immunogen. Because the isoforms a and b of FANCD2 are different in their c-terminal sequence, this antibody should not be able to differentiate the isoforms.
3. Where does the FANCD2 Ab specifically recognizes on the protein? I see that it recognizes the N-terminus but could you tell me which AA range exactly?
   • The amino acid range for this antibody corresponds to amino acids 11-230 [Swiss-Prot #Q9BXW9].https://www.uniprot.org/uniprot/Q9BXW9#sequences

Bioinformatics

• Gene Symbol: FANCD2